WO2025079039 - ANTI-PD-1-BASED TREATMENT BEFORE AND AFTER SURGERY
National phase entry:
Publication Number
WO/2025/079039
Publication Date
17.04.2025
International Application No.
PCT/IB2024/059994
International Filing Date
11.10.2024
Title **
[English]
ANTI-PD-1-BASED TREATMENT BEFORE AND AFTER SURGERY
[French]
TRAITEMENT À BASE D'ANTI-PD-1 AVANT ET APRÈS CHIRURGIE
Applicants **
BEONE MEDICINES I GMBH
BEONE GUANGZHOU BIOLOGICS MANUFACTURING CO., LTD.
Inventors
ZHENG, Wenjuan
WANG, Ruihua
ZHANG, Qiuyang
Priority Data
PCT/CN2023/124264
12.10.2023
CN
PCT/CN2023/135545
30.11.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5306 | |
| EPO | Filing, Examination, Granting | 74416 | |
| Japan | Filing, Examination, Granting | 4317 | |
| South Korea | Filing, Examination, Granting | 6344 | |
| USA | Filing, Examination, Granting | 19490 |
Total:
109,873
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure relates to treatment of solid cancers, such as breast, colon and lung cancer (in particular, non-small cell lung cancer (NSCLC)) in human subjects with an anti-PD-1 antibody as monotherapy or as combination therapy with for example chemotherapy and/or surgery. The provided treatment may be Tislelizumab in combination with chemotherapy prior to surgery, with a different dose of Tislelizumab in the adjuvant phase following surgery. The administration regimen may include administration of 200 mg of an anti-PD-1 antibody (e.g., tislelizumab) (e.g., every three weeks), followed by tumor resection, and administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and/or cisplatin), and may further include pemetrexed (e.g., for non-squamous carcinoma) or paclitaxel (e.g., for squamous carcinoma).[French]
La divulgation vise à traiter des cancers solides, tels que le cancer du sein, du côlon et du poumon (en particulier, le cancer du poumon non à petites cellules (NSCLC)) chez des sujets humains avec un anticorps anti-PD-1 en tant que monothérapie ou en tant que polythérapie avec par exemple une chimiothérapie et/ou une chirurgie. Le traitement fourni peut être le tislelizumab en combinaison avec une chimiothérapie avant la chirurgie, avec une dose différente de tislelizumab dans la phase adjuvante après chirurgie. La posologie d'administration peut comprendre l'administration de 200 mg d'un anticorps anti-PD-1 (par exemple, le tislelizumab) (par exemple, toutes les trois semaines), suivie d'une résection tumorale, et l'administration de 400 mg de l'anticorps anti-PD-1 (par exemple, toutes les six semaines). En outre, la chimiothérapie peut être à base de platine (par exemple, le carboplatine et/ou le cisplatine), et peut en outre comprendre du pémétrexed (par exemple, pour un carcinome non squameux) ou du paclitaxel (par exemple, pour un carcinome squameux).